3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Metformin
2
rosiglitazone-metformin combination
1
mirabegron
1
lorcaserin
1
exemestane
1
atezolizumab
1
angiotensin I (1-7)
1
Traumeel S
1
Tirzepatide
1
TIC10 compound
1
Sodium Chloride
1
Rosiglitazone
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Melphalan
1
Leflunomide
1
Hydroquinones
1
Fish Oils
1
Fibroblast Growth Factor 7
1
Drug Therapy
1
Docosahexaenoic Acids
1
Cisplatin
1
Cholestyramine Resin
1
CBLB502
1
Ascorbic Acid
1
Acupuncture Therapy
1
ART123
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
angiotensin I (1-7)
×
Other
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled